Trastuzumab deruxtecan (T-DXd)
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-positive Gastric Cancer
Conditions
HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction
Trial Timeline
Feb 27, 2025 → Jul 31, 2027
NCT ID
NCT06846996About Trastuzumab deruxtecan (T-DXd)
Trastuzumab deruxtecan (T-DXd) is a pre-clinical stage product being developed by Daiichi Sankyo for HER2-positive Gastric Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06846996. Target conditions include HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction.
What happened to similar drugs?
0 of 15 similar drugs in HER2-positive Gastric Cancer were approved
Approved (0) Terminated (0) Active (15)
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06846996 | Pre-clinical | Recruiting |
Competing Products
20 competing products in HER2-positive Gastric Cancer